Axcella

840 Memorial Drive
Entrance on Blackstone Street, Third Floor
Cambridge
Massachusetts
02139
United States

Tel: 857-320-2200
Fax: 617-441-6243

Email: info@axcellahealth.com

Show jobs for this employer

About Axcella

Axcella Health is pioneering revolutionary new medicines with a focus on amino acid homeostasis. The company has discovered more than 2,000 diseases with amino acid imbalances and developed a systems pharmacology approach to restore health at the cellular level. Axcella’s proprietary platform is clinically validated across several indication areas, with clinical-stage candidates in muscle, neurodegenerative and liver conditions. Axcella is led by a team with a strong track record of leaving a lasting impact on the therapeutic landscape through the development of novel products. The company was founded by VentureLabs, the Innovation Foundry at Flagship Ventures, and has received additional funding from Fidelity Research & Management Group, Gurnet Point Capital and Nestlé Health Science. Axcella is based in Cambridge, Mass.
YEAR FOUNDED:
2010
LEADERSHIP:
CEO: Robert Connelly
CMO: Christopher I. Wright
CFO: Thomas Leggett
JOBS:
Please click here for Axcella job opportunities.

47 articles with Axcella

  • Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced two upcoming poster presentations at The Liver Meeting ® 2020, the Annual Meeting of the American Association for the Study of Liver Dise

  • iScience review paper details use of amino acids in medicine Axcella focused on designing novel EMM compositions with the potential to tackle complex diseases; plans to advance lead candidates into later-stage clinical trials CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) com

  • Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that management will be participating in a fireside chat at the H.C. Wainwright 4th Annual NASH In

  • Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers and Shakers.
  • Axcella (Nasdaq: AXLA) is a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health. The company’s product candidates are comprised of EMMs and their derivatives that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. Axcella’s pipeline includes lead therapeutic can

  • Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced that management will be presenting at the following upcoming conferences: H.C. Wainwright 22nd Annual Global Investment Conf

  • Poster presentation contains data demonstrating AXA1125’s multifactorial effects on markers of metabolism, inflammation and fibrosis in subjects with NAFLD CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, announced that data are being presented today in a late-

  • Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced an upcoming late-breaker poster presentation at The Digital International Liver Congress™ 2020 (EASL), which is being held virtually from August 27 to 29. This presentation will discuss key data from A

  • Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex

  • Top-line data from AXA1665-002 show dose dependent improvements in markers of cognitive function and amino acid metabolism; both AXA1665 doses safe and well tolerated for 12 Weeks; plan to initiate Phase 2 clinical trial under IND in 1H 2021

  • Top-line data from AXA1665-002 show dose dependent improvements in markers of cognitive function and amino acid metabolism; both AXA1665 doses safe and well tolerated for 12 Weeks; plan to initiate Phase 2 clinical trial under IND in 1H 2021 Reported positive top-line data for AXA1125, Axcella’s NASH product candidate, with clinically relevant reductions in liver fat content, insulin resistance and fibroinflammation; plan to initiate Phase 2b clini

  • Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced that it plans to report its second quarter financial results and other business updates on August 5, 2020. The company will host a conference call at 8

  • Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today anno

  • Presentation and webcast to take place at 3:50 p.m. ET on June 10

  • Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced the closing of its underwritten public offering of an aggregate of 12,650,000 shares of its common stock, including the full exercise of the underwriters’ option to purchase additional shares,

  • Axcella, a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators to pioneer a new approach for treating complex diseases and improving health, announced the pricing of its underwritten public offering of 11,000,000 shares of its common stock at a public offering price of $4.75 per share, before deducting underwriting discounts and commissions.

  • Reported positive top-line data from AXA1125-003, with clinically relevant reductions in liver fat content, insulin resistance and fibroinflammation observed in subjects with NAFLD receiving AXA1125 Completed enrollment of AXA1665-002, with data readout expected in Q3 2020 Announced AXA2678 patent issuance and oral presentation at ICSFR Launched new corporate website at www.axcellahealth.com CAMBRIDGE, Mass.--( BUSINE

  • The race has been ongoing to develop an approved therapy for nonalcoholic steatohepatitis (NASH) and Axcella is moving closer to the goal line following positive topline data from a clinical study dubbed AXA1125-003.
  • May 6, 2020 12:00 UTC Clinically relevant reductions in liver fat content, insulin resistance and fibroinflammation markers observed with AXA1125 along with favorable tolerability, supporting its potential to be a first-line NASH therapy Greater activity in key markers seen among subjects with type 2 diabetes receiving AXA1125 Company plans to engage with FDA regarding IND submission for AXA1125, proposed Phase 2b clinical trial in adult NASH and pediatric dev

  • Axcella, a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators to pioneer a new approach for treating complex diseases and improving health, announced that it plans to report top-line data from AXA1125-003 on May 6, 2020 and will host a conference call at 8:30 a.m. ET that morning.